FindTrial
Sign In

Radiomics study on the therapeutic prognosis of Conbercept in the treatment of macular edema secondary to retinal vein occlusion

Radiomics study on the therapeutic prognosis of Conbercept in the treatment of macular edema secondary to retinal vein occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104229
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

BRVO group:None
CRVO group:None
Control group:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed RVO patients with a disease course within 3 months; 2. Adults over 18 years old; 3. There is no history of cataract surgery within 6 months; 4. There is no history of fundus diseases, uveitis, high myopia, glaucoma, ocular trauma or vitreous surgery;

Exclusion criteria

Exclusion criteria: 1. Patients with treated RVO; 2. Patients with diabetic retinopathy at the same time; 3. Uveitis, high myopia, glaucoma, history of ocular trauma and vitreous surgery; 4. There is a history of cataract surgery within 6 months; 5. Patients with newly developed systemic cardiovascular events;

Design outcomes

Primary

MeasureTime frame
Radiomics biomarkers;—

Secondary

MeasureTime frame
CNP,ISI;retinal thickness;times of injection;—

Countries

China

Contacts

Public ContactXi Shen

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

carl_shen2005@126.com+86 136 2167 7680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026